CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 304 enrolled
Drug / intervention
ABT-493/ABT-530 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02640482
NCT02640482Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

AbbVie·interventional·Posted Dec 29, 2015·Updated Jul 16, 2021

In Brief

A Phase 3 clinical trial evaluating ABT-493/ABT-530 and Placebo for ABT-493/ABT-530 for Chronic Hepatitis C Virus (HCV) Infection. Completed, enrolled 304 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus (HCV) Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 29, 2015
Enrollment StartNov 1, 2015
Primary CompletionSep 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.5 years ago

Interventions

ABT-493/ABT-530drug

Tablet; ABT-493 coformulated with ABT-530

Placebo for ABT-493/ABT-530drug

tablet